Amendments to the Claims:

Please cancel claims 1 - 17. Please add 18-34 as follows:

Claims 1-17 (canceled)

Claim 18 (new) A nasal pharmaceutical composition which comprises
(a) at least one active substance suitable for nasal administration, which active substance is selected from the group consisting of xylometazoline, naphazoline, fenoxazoline, oxymetazoline, tetrahydrozoline, tramazoline, phenylephrine, ephedrine, epinephrine, and nasally acceptable salts of any of these compounds,
(b) a mucopolysaccharide which is selected from the group consisting of chondroitin, hyaluronic acid, dermatan, keratan, heparin, acemannan, and nasally acceptable salts of any of said compounds, and
(c) propylene glycol.

Claim 19 (new) A composition according to claim 18, wherein the active substance (a) is xylometazoline or a nasally acceptable salt thereof.

Claim 20 (new) A composition according to claim 18, wherein the mucopolysaccharide (b) is chondroitin sulfate.

Claim 21 (new) A composition according to claim 18, wherein propylene glycol (c) is present in an amount of from 0.5 up to 10 % (w/w) of the total composition.

Claim 22 (new) A composition according to claim 18, wherein propylene glycol (c) is present in an amount of from 1.5 up to 5 % (w/w) of the total composition.

Claim 23 (new) A composition according to claim 18, wherein the composition further comprises water as vehicle.

Claim 24 (new) A composition according claim 18, wherein the composition further comprises a nasally acceptable film-forming agent.

Claim 25 (new) A composition according to claim 18, wherein the composition further comprises an essential oil of a plant.

Claim 26 (new) A composition according to claim 18, wherein the composition further comprises a nasally acceptable preservative.

Claim 27 (new) A composition according to claim 18, wherein the composition is devoid of a nasally acceptable preservative.

Claim 28 (new) A nasal pharmaceutical composition which consists essentially of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol, and
(d) water,
with the proviso that said composition is devoid of fexofenadine and pharmaceutically acceptable salts thereof.

Claim 29 (new) A nasal pharmaceutical composition which consists essentially of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol,
(d) a nasally acceptable preservative, and
(e) water,
with the proviso that said composition is devoid of fexofenadine and pharmaceutically acceptable salts thereof.

Claim 30 (new) A composition according to claim 28, wherein the active substance (a) is selected from the group consisting of xylometazoline, naphazoline, fenoxazoline, oxymetazoline, tetrahydrozoline, tramazoline, phenylephrine, ephedrine, epinephrine, and nasally acceptable salts of any of these compounds.

Claim 31 (new) A composition according to claim 28, wherein the active substance (a) is xylometazoline or a nasally acceptable salt thereof.

Claim 32 (new) A nasal pharmaceutical composition according to claim 28, wherein the mucopolysaccharide (b) is selected from the group consisting of chondroitin, hyaluronic acid, dermatan, keratan, heparin, acemannan, and nasally acceptable salts of any of said compounds.

Claim 33 (new) A composition according to claim 32, wherein the mucopolysaccaride (b) is chondrotin sulfate.

Claim 34 (new) A composition according to claim 18, wherein the composition is in the form of drops, a solution, a spray or a metered-dose spray.